Dina Ben Yehuda
Overview
Explore the profile of Dina Ben Yehuda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1792
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abd-Elrahman I, Nassar T, Khairi N, Perlman R, Benita S, Yehuda D
Oncogene
. 2025 Jan;
44(7):477.
PMID: 39881016
No abstract available.
2.
Rosen-Zvi M, Friedman N, Yehuda D
Harefuah
. 2024 Nov;
163(10):663-667.
PMID: 39535018
Artificial Intelligence (AI) has become a key tool for the acceleration of scientific discovery, from accelerated drug discovery through automatic-robotic lab to the discovery of new materials that can help...
3.
Aumann S, Tsubary U, Nachmias B, Yehuda D, Lavie D, Goldschmidt N, et al.
Eur J Haematol
. 2023 Apr;
111(1):135-145.
PMID: 37096337
Background: Studies addressing coronavirus disease 2019 (COVID-19) in patients with hematological malignancies have reported mortality rates of up to 40%; however, included predominantly hospitalized patients. Methods: During the first year...
4.
Dimopoulos M, Oriol A, Nahi H, San-Miguel J, Bahlis N, Usmani S, et al.
J Clin Oncol
. 2023 Jan;
41(8):1590-1599.
PMID: 36599114
Purpose: With the initial analysis of POLLUX at a median follow-up of 13.5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone...
5.
Abd-Elrahman I, Nassar T, Khairi N, Perlman R, Benita S, Yehuda D
Oncogene
. 2020 Oct;
40(2):334-344.
PMID: 33128043
We previously showed that Livin, an inhibitor of apoptosis protein, is specifically cleaved to produce a truncated protein, tLivin, and demonstrated its paradoxical proapoptotic activity. We further demonstrated that mini-tLivin...
6.
Oberbaum M, Shaham D, Toledano M, Halevy J, Yehuda D
Harefuah
. 2019 Nov;
158(11):724-727.
PMID: 31721515
The use of complementary and alternative medicine (CAM) has become increasingly popular in most Western countries. As a result, safety-related issues associated with these practices have become more apparent, including...
7.
Ledergor G, Weiner A, Zada M, Wang S, Cohen Y, Gatt M, et al.
Nat Med
. 2018 Dec;
24(12):1867-1876.
PMID: 30523328
Multiple myeloma, a plasma cell malignancy, is the second most common blood cancer. Despite extensive research, disease heterogeneity is poorly characterized, hampering efforts for early diagnosis and improved treatments. Here,...
8.
Clarfield A, Skorecki K, Paltiel O, Glick S, Beyar R, Yehuda D, et al.
Am J Public Health
. 2018 Nov;
108(12):1624-1625.
PMID: 30403519
No abstract available.
9.
Trneny M, Verhoef G, Dyer M, Yehuda D, Patti C, Canales M, et al.
Haematologica
. 2018 May;
103(8):1351-1358.
PMID: 29748443
This phase II, single-arm, multicenter study examined the efficacy and safety of coltuximab ravtansine (an anti-CD19 antibody drug conjugate) in 61 patients with histologically documented ( or transformed) relapsed or...
10.
Kleinstern G, Averbuch M, Abu Seir R, Perlman R, Yehuda D, Paltiel O
Hematol Oncol
. 2018 Feb;
36(2):457-462.
PMID: 29469175
Although autoimmune diseases (AIDs) are known to predispose to non-Hodgkin lymphoma (NHL), their association with NHL prognosis has rarely been investigated. We examined associations between autoimmunity and B-cell NHL onset...